

Remarks

With respect to the Examiner's question regarding claim 61, part (a) encompassing an antibody which is both monoclonal and chimeric, Applicants offer the following explanation. Applicants submit that chimeric antibodies can be monoclonal, for example, by virtue of their production from identical genetic sequences in the absence of chimeric (or other) antibodies encoded by dissimilar generic sequences (*i.e.*, by DNA sequences encoding antibodies having a different polypeptide sequence.) This would be in contrast, for example, to chimeric antibodies produced by a population of cells wherein said cells encode non-identical chimeric antibodies (*e.g.*, chimeric antibodies having different antigen binding specificities).


Conclusion

Entry of the above amendments is respectfully requested. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicant would expedite the examination of this application.

Finally, if any fees not already accounted for are due in connection with the filing of this paper, please charge such fees to our Deposit Account No. 08-3425.

Respectfully submitted,

Date: 2/3/2005


Doyle A. Siever (Reg. No. 47,088)
Agent for Applicants

Human Genome Sciences, Inc.
Intellectual Property Department
14200 Shady Grove Road
Rockville, MD 20850
(301) 354-3932 (telephone)

KKH/DAS/mr